Jaap Verweij
Impact in
- Gastroenterology top 0.01%
- Gastrointestinal Tumor Research and Treatment
- Oncology top 0.01%
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Vascular Tumors and Angiosarcomas
Papers in
- Oncology 303
- Cancer Treatment and Pharmacology 115
- Neutropenia and Cancer Infections 49
- Drug Transport and Resistance Mechanisms 43
- Lung Cancer Research Studies 42
- Colorectal Cancer Treatments and Studies 38
-
- Cancer therapeutics and mechanisms 142
- Co-authors
- M. van Glabbeke (55 shared papers)Alex Sparreboom (149 shared papers)Allan T. van Oosterom (14 shared papers)J. Wanders (27 shared papers)Elizabeth A. Eisenhauer (5 shared papers)Patrick Therasse (4 shared papers)Larry Rubinstein (4 shared papers)Susan G. Arbuck (3 shared papers)
- Journals
- European Journal of Cancer (96 papers)Journal of Clinical Oncology (86 papers)British Journal of Cancer (48 papers)Annals of Oncology (47 papers)Clinical Cancer Research (32 papers)
- Partner nations
- NetherlandsUnited StatesBelgium
In The Last Decade
Jaap Verweij
621 papers receiving 55.8k citations
Jaap Verweij's Hit Papers
Peers
Comparison fields: 5 of 189
- Gastroenterology 6.5k
- Oncology 20.5k
- Pulmonary and Respiratory Medicine 16.6k
- Cancer Research 3.9k
- Hepatology 1.8k
Countries citing papers authored by Jaap Verweij
This map shows the geographic impact of Jaap Verweij's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaap Verweij with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaap Verweij more than expected).
Fields of papers citing papers by Jaap Verweij
This network shows the impact of papers produced by Jaap Verweij. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaap Verweij. The network helps show where Jaap Verweij may publish in the future.
Co-authors
The 25 scholars most cited alongside Jaap Verweij, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 627 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | New Guidelines to Evaluate the Response to Treatment in Solid Tumors Hit paper breakdown → | 2000 | 13832 |
| 2 | Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Hit paper breakdown → | 2006 | 2041 |
| 3 | Cremophor EL Hit paper breakdown → | 2001 | 1440 |
| 4 | Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Hit paper breakdown → | 2004 | 1344 |
| 5 | Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Hit paper breakdown → | 2001 | 1026 |
| 6 | Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Hit paper breakdown → | 2014 | 838 |
| 7 | KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Hit paper breakdown → | 2006 | 693 |
| 8 | Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas Hit paper breakdown → | 2009 | 635 |
| 9 | Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors Hit paper breakdown → | 2011 | 574 |
| 10 | Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043) Hit paper breakdown → | 2009 | 553 |
| 11 | Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study Hit paper breakdown → | 2010 | 524 |
| 12 | Pharmacological Effects of Formulation Vehicles Hit paper breakdown → | 2003 | 509 |
| 13 | 2005 | 481 | |
| 14 | Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study Hit paper breakdown → | 1999 | 456 |
| 15 | Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Hit paper breakdown → | 1995 | 438 |
| 16 | Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial Hit paper breakdown → | 2012 | 400 |
| 17 | 1997 | 393 | |
| 18 | 2004 | 375 | |
| 19 | 1998 | 364 | |
| 20 | 2005 | 355 |
About Jaap Verweij
Jaap Verweij is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Gastroenterology and Surgery, having authored 627 papers that have together received 57.7k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (142 papers), Cancer Treatment and Pharmacology (115 papers), Sarcoma Diagnosis and Treatment (92 papers), Gastrointestinal Tumor Research and Treatment (62 papers), Neutropenia and Cancer Infections (49 papers), Drug Transport and Resistance Mechanisms (43 papers), Lung Cancer Research Studies (42 papers) and Colorectal Cancer Treatments and Studies (38 papers). The work is most often cited by research in Gastroenterology (6.5k citations), Oncology (20.5k citations), Pulmonary and Respiratory Medicine (16.6k citations), Cancer Research (3.9k citations) and Hepatology (1.8k citations). Jaap Verweij has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include M. van Glabbeke, Alex Sparreboom, Allan T. van Oosterom, J. Wanders, Elizabeth A. Eisenhauer, Patrick Therasse, Larry Rubinstein, Susan G. Arbuck, Richard Kaplan and Michaele C. Christian. Their work appears in journals such as European Journal of Cancer, Journal of Clinical Oncology, British Journal of Cancer, Annals of Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.